Studies reveal that APOE, particularly its ε4 allele—a known risk factor for late-onset AD (Nicolas, 2024)-acts as an agonist in this interaction, affecting AD pathology through the TREM2-APOE complex (Bailey et al., 2015; Jendresen et al., 2017). Here, TREM2 is linked to Alzheimer disease.